New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.

In this retrospective real-world study treatment with NOAC showed to be associated with significant reductions of CV events and bleeding events compared to VKA use, albeit at a higher NHS' direct cost per patient/year, mainly due to higher drug therapy cost.